Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo/Kite’s CAR-T Cell Therapy Scoops Up Orphan Status for B-Cell Lymphoma
October 4, 2018
- Bavencio on Back Foot, but Merck KGaA Has High Hopes for Next-Gen I/O Therapy M7824
October 3, 2018
- Fujifilm, Taisho Detail Sales Schemes after Tie-Up Dissolution Next March
October 3, 2018
- Kaken Grants Distribution Rights for Efinaconazole to Main Life in Hong Kong, Macau
October 3, 2018
- Adcetris Improves PFS as Frontline Therapy for PTCL in PIII: Takeda/Seattle Genetics
October 3, 2018
- Ono to Transfer 5 Established Injectable Brands to Maruishi
October 2, 2018
- FDA OKs Pediatric Label Expansion for Fycompa: Eisai
October 2, 2018
- Alnylam Files Patisiran in Japan, Anticipates Nod in Mid-2019
October 2, 2018
- Astellas Seeks Approval for Japan’s 1st HIF-PH Inhibitor Roxadustat
October 2, 2018
- Wholesalers See “Some Reduction in Yakkasa” in Price Negotiations under New Guidelines: Will Reduction Continue?
October 2, 2018
- Maruho Licenses Cancer Stomatitis Treatment from NCC
October 2, 2018
- Konica Minolta Embarks on Precision Medicine Biz, Ex-GSK/AZ Exec Takes Helm
October 1, 2018
- 5 Years after Transparency Guidelines Rollout, R&D Costs Halve while Dining Outlays About to Disappear
October 1, 2018
- Maruho Takes Over Differin Gel Marketing Authorization from Galderma
October 1, 2018
- Vortioxetine Filed in Japan for MDD: Takeda/Lundbeck
October 1, 2018
- Hisamitsu Files Transdermal Parkinson’s Disease Drug in Japan
October 1, 2018
- 2 Camps of Biosimilar Makers Seek Japan Approval for Nesp Follow-Ons
October 1, 2018
- Takeda Touts Progress in R&D Makeover, Departure from Small Molecules
September 28, 2018
- Kyorin, Teijin Dissolve Capital Alliance
September 28, 2018
- Alnylam Plants Flag in Japan Soil, Eyes 4 RNAi Therapeutic Launches in 5 Years
September 28, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…